Download PDF
Semin Thromb Hemost 2017; 43(01): 059-068
DOI: 10.1055/s-0036-1585076
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Developing the First Recombinant Factor XIII for Congenital Factor XIII Deficiency: Clinical Challenges and Successes

Manuel Carcao
1   Division of Haematology/Oncology, Department of Paediatrics and Child Health Evaluative Sciences, Research Institute, Hospital for Sick Children, University of Toronto, Toronto, Canada
,
Katsuyuki Fukutake
2   Department of Laboratory Medicine, Tokyo Medical University, Tokyo, Japan
,
Aida Inbal
3   Thrombosis and Hemostasis Unit, Rabin Medical Center, Petah Tikva, Israel
4   Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
,
Bryce Kerlin
5   Nationwide Children's Hospital, The Ohio State University College of Medicine, Ohio
,
Riitta Lassila
6   Coagulation Disorders Unit, Hematology and Cancer Center and Clinical Chemistry, Helsinki University Hospital, Helsinki, Finland
,
Johannes Oldenburg
7   Institute for Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany
,
May-Lill Garly
8   Novo Nordisk A/S, Søborg, Denmark
,
Diane Nugent
9   Children's Hospital of Orange County, UC Irvine School of Medicine, Orange, California
› Author Affiliations
Further Information

Publication History

Publication Date:
24 August 2016 (online)

    Permissions and Reprints

Abstract

Congenital factor XIII (FXIII) deficiency is a rare, autosomal recessive bleeding disorder with potentially life-threatening consequences. FXIII is composed of two subunits (A and B), and a deficiency or dysfunction of either can result in FXIII deficiency. Traditionally, FXIII deficiency has been managed by infusing plasma-derived products containing FXIII (fresh frozen plasma, cryoprecipitate, and plasma-derived FXIII concentrates), all of which contain both subunits. Despite the increased safety of plasma-derived products, concern remains regarding potential viral safety issues. This review describes the development, from concept to clinical use, of a recombinant FXIII molecule (containing subunit A only; rFXIII-A2) for congenital FXIII-A subunit deficiency. Unmet needs and ongoing challenges in congenital FXIII deficiency are also discussed. Despite the challenges in developing a product for a very rare bleeding disorder, the information gathered on efficacy, safety, and pharmacokinetics of FXIII replacement therapy represents the largest dataset on congenital FXIII-A subunit deficiency in the world. It also provides evidence for the safety and efficacy of monthly prophylaxis with 35 IU/kg of rFXIII-A2 in patients with FXIII-A subunit deficiency. The issues encountered and overcome, along with lessons learned, may be applied to and encourage the development of new recombinant products for other rare bleeding disorders.

Keywords

congenital FXIII deficiency - recombinant factor XIII - prophylaxis
 

  • References

  • 1 Bolton-Maggs PH, Perry DJ, Chalmers EA , et al. The rare coagulation disorders—review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004; 10 (5) 593-628
    CrossrefPubMedSearch in Google Scholar
  • 2 Di Paola J, Nugent D, Young G. Current therapy for rare factor deficiencies. Haemophilia 2001; 7 (Suppl. 01) 16-22
    PubMedSearch in Google Scholar
  • 3 Peyvandi F, Palla R, Menegatti M , et al; European Network of Rare Bleeding Disorders Group. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost 2012; 10 (4) 615-621
    CrossrefPubMedSearch in Google Scholar
  • 4 World Federation of Haemophilia. Report on Annual Global Survey 2014. Available at http://www1.wfh.org/publications/files/pdf-1627.pdf . Accessed February 2, 2016
    PubMed
  • 5 Karimi M, Bereczky Z, Cohan N, Muszbek L. Factor XIII deficiency. Semin Thromb Hemost 2009; 35 (4) 426-438
    Thieme ConnectPubMedSearch in Google Scholar
  • 6 Nugent DJ. Prophylaxis in rare coagulation disorders—factor XIII deficiency. Thromb Res 2006; 118 (Suppl. 01) S23-S28
    CrossrefPubMedSearch in Google Scholar
  • 7 European Medicines Agency. Assessement Report NovoThirteen (catridecacog). Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002284/WC500132999.pdf . Accessed July 23, 2015
    PubMed
  • 8 Hur WS, Mazinani N, Lu XJ , et al. Coagulation factor XIIIa is inactivated by plasmin. Blood 2015; 126 (20) 2329-2337
    CrossrefPubMedSearch in Google Scholar
  • 9 Duckert F, Jung E, Shmerling DH. A hitherto undescribed congenital haemorrhagic diathesis probably due to fibrin stabilizing factor deficiency. Thromb Diath Haemorrh 1960; 5: 179-186
    PubMedSearch in Google Scholar
  • 10 Naderi M, Dorgalaleh A, Alizadeh S , et al. Polymorphism of thrombin-activatable fibrinolysis inhibitor and risk of intracranial haemorrhage in factor XIII deficiency. Haemophilia 2014; 20 (1) e89-e92
    CrossrefPubMedSearch in Google Scholar
  • 11 Sharief LA, Kadir RA. Congenital factor XIII deficiency in women: a systematic review of literature. Haemophilia 2013; 19 (6) e349-e357
    CrossrefPubMedSearch in Google Scholar
  • 12 Anwar R, Miloszewski KJ. Factor XIII deficiency. Br J Haematol 1999; 107 (3) 468-484
    CrossrefPubMedSearch in Google Scholar
  • 13 Hsieh L, Nugent D. Factor XIII deficiency. Haemophilia 2008; 14 (6) 1190-1200
    CrossrefPubMedSearch in Google Scholar
  • 14 Ivaskevicius V, Biswas A, Thomas A, Tehranchi R, Oldenburg J. Genetic background in patients with severe factor FXIII A-subunit deficiency treated with recombinant FXIII. Blood 2012; 120: 1125
    PubMedSearch in Google Scholar
  • 15 Ivaskevicius V, Seitz R, Kohler HP , et al; Study Group. International registry on factor XIII deficiency: a basis formed mostly on European data. Thromb Haemost 2007; 97 (6) 914-921
    Thieme ConnectPubMedSearch in Google Scholar
  • 16 Ivaskevicius V, Windyga J, Baran B , et al. Phenotype-genotype correlation in eight Polish patients with inherited Factor XIII deficiency: identification of three novel mutations. Haemophilia 2007; 13 (5) 649-657
    CrossrefPubMedSearch in Google Scholar
  • 17 Egbring R, Kröniger A, Seitz R. Factor XIII deficiency: pathogenic mechanisms and clinical significance. Semin Thromb Hemost 1996; 22 (5) 419-425
    Thieme ConnectPubMedSearch in Google Scholar
  • 18 Janbain M, Nugent DJ, Powell JS, St-Louis J, Frame VB, Leissinger CA. Use of factor XIII (FXIII) concentrate in patients with congenital FXIII deficiency undergoing surgical procedures. Transfusion 2015; 55 (1) 45-50
    CrossrefPubMedSearch in Google Scholar
  • 19 Kohler HP, Ichinose A, Seitz R, Ariens RA, Muszbek L ; Factor XIII And Fibrinogen SSC Subcommittee Of The ISTH. Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost 2011; 9 (7) 1404-1406
    CrossrefPubMedSearch in Google Scholar
  • 20 Tahlan A, Ahluwalia J. Factor XIII: congenital deficiency factor XIII, acquired deficiency, factor XIII A-subunit, and factor XIII B-subunit. Arch Pathol Lab Med 2014; 138 (2) 278-281
    CrossrefPubMedSearch in Google Scholar
  • 21 Ichinose A, Osaki T, Souri M ; Japanese Collaborative Research Group (JCRG) on AH13 (supported by the Japanese Ministry of Health, Labor, and Welfare). Clinical features of 32 new Japanese cases with autoimmune haemorrha-philia due to anti-factor XIII antibodies. Haemophilia 2015; 21 (5) 653-658
    CrossrefPubMedSearch in Google Scholar
  • 22 Osaki T, Sugiyama D, Magari Y, Souri M, Ichinose A. Rapid immunochromatographic test for detection of anti-factor XIII A subunit antibodies can diagnose 90 % of cases with autoimmune haemorrhaphilia XIII/13. Thromb Haemost 2015; 113 (6) 1347-1356
    Thieme ConnectPubMedSearch in Google Scholar
  • 23 Rand ML, Clark DS, Abdel-Samad N , et al. Factor XIII (FXIII) deficiency in Canada: description of the national cohort. Haemophilia 2014; 20 (Suppl. 03) 101
    CrossrefPubMedSearch in Google Scholar
  • 24 Inbal A, Oldenburg J, Carcao M, Rosholm A, Tehranchi R, Nugent D. Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency. Blood 2012; 119 (22) 5111-5117
    CrossrefPubMedSearch in Google Scholar
  • 25 Ashley C, Chang E, Davis J, Mangione A, Frame V, Nugent DJ. Efficacy and safety of prophylactic treatment with plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency. Haemophilia 2015; 21 (1) 102-108
    CrossrefPubMedSearch in Google Scholar
  • 26 Nugent DJ, Ashley C, García-Talavera J, Lo LC, Mehdi AS, Mangione A. Pharmacokinetics and safety of plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency. Haemophilia 2015; 21 (1) 95-101
    PubMedSearch in Google Scholar
  • 27 Novo Nordisk. NovoThirteen summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/002284/WC500132997.pdf . Accessed July 23, 2015
    PubMed
  • 28 Ponce RA, Visich JE, Heffernan JK , et al. Preclinical safety and pharmacokinetics of recombinant human factor XIII. Toxicol Pathol 2005; 33 (4) 495-506
    CrossrefPubMedSearch in Google Scholar
  • 29 Reynolds TC, Butine MD, Visich JE , et al. Safety, pharmacokinetics, and immunogenicity of single-dose rFXIII administration to healthy volunteers. J Thromb Haemost 2005; 3 (5) 922-928
    CrossrefPubMedSearch in Google Scholar
  • 30 Visich JE, Zuckerman LA, Butine MD , et al. Safety and pharmacokinetics of recombinant factor XIII in healthy volunteers: a randomized, placebo-controlled, double-blind, multi-dose study. Thromb Haemost 2005; 94 (4) 802-807
    Thieme ConnectPubMedSearch in Google Scholar
  • 31 Lovejoy AE, Reynolds TC, Visich JE , et al. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. Blood 2006; 108 (1) 57-62
    CrossrefPubMedSearch in Google Scholar
  • 32 Carcao M, Inbal A, Kerlin B, Brand-Staufer B, Garly M-L. Efficacy, safety and pharmacokinetics of recombinant FXIII at steady-state in patients with congenital FXIII-A subunit deficiency. Haemophilia 2014; 20 (Suppl. 03) 104
    CrossrefPubMedSearch in Google Scholar
  • 33 Brand-Staufer B, Carcao M, Kerlin BA , et al. Pharmacokinetic characterization of recombinant factor XIII (FXIII)-A2 across age groups in patients with FXIII A-subunit congenital deficiency. Haemophilia 2015; 21 (3) 380-385
    CrossrefPubMedSearch in Google Scholar
  • 34 Kerlin B, Brand B, Inbal A , et al. Pharmacokinetics of recombinant factor XIII at steady state in patients with congenital factor XIII A-subunit deficiency. J Thromb Haemost 2014; 12 (12) 2038-2043
    CrossrefPubMedSearch in Google Scholar
  • 35 Fukutake K, Carcao M, Inbal A , et al. New data on the safety and efficacy of recombinant FXIII in patients with congenital FXIII deficiency. Blood 2014; 124 (21) 1520
    PubMedSearch in Google Scholar
  • 36 Williams M, Will A, Stenmo C, Rosholm A, Tehranchi R. Pharmacokinetics of recombinant factor XIII in young children with congenital FXIII deficiency and comparison with older patients. Haemophilia 2014; 20 (1) 99-105
    PubMedSearch in Google Scholar
  • 37 Peyvandi F, Di Michele D, Bolton-Maggs PH, Lee CA, Tripodi A, Srivastava A ; Project on Consensus Definitions in Rare Bleeding Disorders of the Factor VIII/Factor IX Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity. J Thromb Haemost 2012; 10 (9) 1938-1943
    CrossrefPubMedSearch in Google Scholar
  • 38 Jennings I, Kitchen S, Woods TA, Preston FE. UK NEQAS. Problems relating to the laboratory diagnosis of factor XIII deficiency: a UK NEQAS study. J Thromb Haemost 2003; 1 (12) 2603-2608
    CrossrefPubMedSearch in Google Scholar
  • 39 Lawrie AS, Green L, Mackie IJ, Liesner R, Machin SJ, Peyvandi F. Factor XIII—an under diagnosed deficiency—are we using the right assays?. J Thromb Haemost 2010; 8 (11) 2478-2482
    CrossrefPubMedSearch in Google Scholar
  • 40 Kappel A, Stephan S, Duwe C , et al. Fully automated immunoassay for quantitative determination of FXIII. Hamostaseologie 2011; 31 (2) 105-109
    Thieme ConnectPubMedSearch in Google Scholar
  • 41 Orosz ZZ, Katona E, Facskó A, Berta A, Muszbek L. A highly sensitive chemiluminescence immunoassay for the measurement of coagulation factor XIII subunits and their complex in tears. J Immunol Methods 2010; 353 (1–2) 87-92
    CrossrefPubMedSearch in Google Scholar
  • 42 Saigusa S, Yamamura T, Tanaka K , et al. Efficacy of administration of coagulation factor XIII with definitive surgery for multiple intractable enterocutaneous fistulae in a patient with decreased factor XIII activity. BMJ Case Rep 2011;
    PubMedSearch in Google Scholar
  • 43 Asahina T, Kobayashi T, Okada Y, Goto J, Terao T. Maternal blood coagulation factor XIII is associated with the development of cytotrophoblastic shell. Placenta 2000; 21 (4) 388-393
    CrossrefPubMedSearch in Google Scholar
  • 44 Burrows RF, Ray JG, Burrows EA. Bleeding risk and reproductive capacity among patients with factor XIII deficiency: a case presentation and review of the literature. Obstet Gynecol Surv 2000; 55 (2) 103-108
    CrossrefPubMedSearch in Google Scholar
  • 45 Mumford AD, Ackroyd S, Alikhan R , et al; BCSH Committee. Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors' Organization guideline on behalf of the British Committee for Standards in Haematology. Br J Haematol 2014; 167 (3) 304-326
    CrossrefPubMedSearch in Google Scholar
  • 46 Sharief LT, Lawrie AS, Mackie IJ, Smith C, Peyvandi F, Kadir RA. Changes in factor XIII level during pregnancy. Haemophilia 2014; 20 (2) e144-e148
    CrossrefPubMedSearch in Google Scholar
  • 47 Asahina T, Kobayashi T, Takeuchi K, Kanayama N. Congenital blood coagulation factor XIII deficiency and successful deliveries: a review of the literature. Obstet Gynecol Surv 2007; 62 (4) 255-260
    CrossrefPubMedSearch in Google Scholar
  • 48 Naderi M, Dorgalaleh A, Alizadeh S , et al. Clinical manifestations and management of life-threatening bleeding in the largest group of patients with severe factor XIII deficiency. Int J Hematol 2014; 100 (5) 443-449
    CrossrefPubMedSearch in Google Scholar